Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Q1 2022 Earnings Conference Call May 6, 2022 8:30 AM ET

Company Participants

Nareg Sagherian - ED, IR

Jerome Durso - President and CEO

Andrew Saik - CFO

Linda Richardson - Chief Commercial Officer

Michelle Berrey - President of Research & Development and Chief Medical Officer

Conference Call Participants

Yasmeen Rahimi - Piper Sandler

Ritu Baral - Cowen

Thomas Smith - SVB

Mayank Mamtani - B. Riley

Jonathan Wolliben - JMP Securities

Brian Abrahams - RBC Capital Markets

Michael Yee - Jefferies

Jay Olson - Oppenheimer

Brian Skorney - Baird

Steve Seedhouse - Raymond James

Joseph Stringer - Needham & Company

Ellie Merle - UBS

Operator

Good morning, and welcome to Intercept Pharmaceuticals Q1 2022 Earnings Conference Call. At this time all participants are in listen-only mode. [Operator Instructions]. As reminder, today's call is being recorded.

I would now turn the conference over your host, Mr. Nareg Sagherian. Sir, you may begin.

Nareg Sagherian

Thank you. Good morning and thank you for joining us on today's call. This morning, we issued a press release announcing our first quarter 2022 results and business update, which is available on our website at interceptpharma.com.

Before we begin our discussion, I'd like to note that during our call, we will be making forward-looking statements, including statements regarding our approved product and clinical development programs, certain regulatory matters, and our strategy, prospects, financial guidance and future commercial and financial performance. Listeners are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this call, and we undertake no obligation to update such statements, except as required by law.

These forward-looking statements are based on estimates and assumptions that, although believed to be reasonable, are inherently uncertain and subject to a number of risks and uncertainties. Some, but not necessarily all of the risk factors that could cause our actual results to differ materially from our historical results or those anticipated or predicted by our forward-looking statements are discussed in this press release and in our periodic public filings with the SEC.

Today's call will begin with prepared remarks from our President and CEO, Jerry Durso; our Chief Commercial Officer, Linda Richardson; President of Research and Development and Chief Medical Officer, Dr. Michelle Berrey; and Chief Financial Officer, Andrew Saik. We will then open the call and take questions. Please limit yourself to one initial question in order to allow time for all questions to be addressed.